Heinz Feldmann

Summary

Affiliation: National Institutes of Health
Country: USA

Publications

  1. pmc The Ebola virus glycoprotein contributes to but is not sufficient for virulence in vivo
    Allison Groseth
    Laboratory of Virology, Division of Intramural Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Hamilton, Montana, USA
    PLoS Pathog 8:e1002847. 2012
  2. pmc Pathogenesis and host response in Syrian hamsters following intranasal infection with Andes virus
    David Safronetz
    Laboratory of Virology, Division of Intramural Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Rocky Mountain Laboratories, Hamilton, Montana, United States of America
    PLoS Pathog 7:e1002426. 2011
  3. pmc In vitro and in vivo activity of ribavirin against Andes virus infection
    David Safronetz
    Laboratory of Virology, Division of Intramural Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Hamilton, Montana, United States of America
    PLoS ONE 6:e23560. 2011
  4. pmc New World hantaviruses activate IFNlambda production in type I IFN-deficient vero E6 cells
    Joseph Prescott
    Laboratory of Virology, Division of Intramural Research, National Institute of Allergy and Infectious Disease, National Institutes of Health, Rocky Mountain Laboratories, Hamilton, Montana, USA
    PLoS ONE 5:e11159. 2010
  5. pmc Detection of Lassa virus, Mali
    David Safronetz
    National Institutes of Health, Hamilton, Montana 59840, USA
    Emerg Infect Dis 16:1123-6. 2010
  6. pmc Cathepsin B & L are not required for ebola virus replication
    Andrea Marzi
    Laboratory of Virology, Division of Intramural Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Hamilton, Montana, United States of America
    PLoS Negl Trop Dis 6:e1923. 2012
  7. pmc Inhibition of novel β coronavirus replication by a combination of interferon-α2b and ribavirin
    Darryl Falzarano
    Disease Modeling and Transmission Unit, Hamilton, MT, USA
    Sci Rep 3:1686. 2013
  8. pmc Comparison of the pathogenicity of Nipah virus isolates from Bangladesh and Malaysia in the Syrian hamster
    Blair L Debuysscher
    Laboratory of Virology, Division of Intramural Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Rocky Mountain Laboratories, Hamilton, Montana, USA
    PLoS Negl Trop Dis 7:e2024. 2013
  9. pmc The use of a mobile laboratory unit in support of patient management and epidemiological surveillance during the 2005 Marburg Outbreak in Angola
    Allen Grolla
    Special Pathogens Program, National Microbiology Laboratory, Public Health Agency of Canada, Winnipeg, Manitoba, Canada
    PLoS Negl Trop Dis 5:e1183. 2011
  10. pmc Ebola virus RNA editing depends on the primary editing site sequence and an upstream secondary structure
    Masfique Mehedi
    Department of Medical Microbiology, University of Manitoba, Winnipeg, Manitoba, Canada Laboratory of Virology, Rocky Mountain Laboratories, Division of Intramural Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Hamilton, Montana, United States of America
    PLoS Pathog 9:e1003677. 2013

Collaborators

Detail Information

Publications71

  1. pmc The Ebola virus glycoprotein contributes to but is not sufficient for virulence in vivo
    Allison Groseth
    Laboratory of Virology, Division of Intramural Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Hamilton, Montana, USA
    PLoS Pathog 8:e1002847. 2012
    ..Thus, while these findings provide direct evidence that GP contributes to filovirus virulence in vivo, they also clearly indicate that other factors are needed for the acquisition of full virulence...
  2. pmc Pathogenesis and host response in Syrian hamsters following intranasal infection with Andes virus
    David Safronetz
    Laboratory of Virology, Division of Intramural Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Rocky Mountain Laboratories, Hamilton, Montana, United States of America
    PLoS Pathog 7:e1002426. 2011
    ....
  3. pmc In vitro and in vivo activity of ribavirin against Andes virus infection
    David Safronetz
    Laboratory of Virology, Division of Intramural Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Hamilton, Montana, United States of America
    PLoS ONE 6:e23560. 2011
    ....
  4. pmc New World hantaviruses activate IFNlambda production in type I IFN-deficient vero E6 cells
    Joseph Prescott
    Laboratory of Virology, Division of Intramural Research, National Institute of Allergy and Infectious Disease, National Institutes of Health, Rocky Mountain Laboratories, Hamilton, Montana, USA
    PLoS ONE 5:e11159. 2010
    ..Interferon lambda, a more recently characterized type III IFN, is transcriptionally controlled much like the type I IFNs, and activates the innate immune system in a similar manner...
  5. pmc Detection of Lassa virus, Mali
    David Safronetz
    National Institutes of Health, Hamilton, Montana 59840, USA
    Emerg Infect Dis 16:1123-6. 2010
    ..We report the isolation and genetic characterization of Lassa virus from an area previously unknown for Lassa fever...
  6. pmc Cathepsin B & L are not required for ebola virus replication
    Andrea Marzi
    Laboratory of Virology, Division of Intramural Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Hamilton, Montana, United States of America
    PLoS Negl Trop Dis 6:e1923. 2012
    ..In conclusion, our results show that CatB and CatL activity is not required for EBOV replication. Furthermore, EBOV glycoprotein cleavage seems to be mediated by an array of proteases making targeted therapeutic approaches difficult...
  7. pmc Inhibition of novel β coronavirus replication by a combination of interferon-α2b and ribavirin
    Darryl Falzarano
    Disease Modeling and Transmission Unit, Hamilton, MT, USA
    Sci Rep 3:1686. 2013
    ..Thus, a combination of interferon-α2b and ribavirin, which are already commonly used in the clinic, may be useful for patient management in the event of future nCoV infections...
  8. pmc Comparison of the pathogenicity of Nipah virus isolates from Bangladesh and Malaysia in the Syrian hamster
    Blair L Debuysscher
    Laboratory of Virology, Division of Intramural Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Rocky Mountain Laboratories, Hamilton, Montana, USA
    PLoS Negl Trop Dis 7:e2024. 2013
    ..This model can be used to study NiV-B pathogenesis, transmission, and countermeasures that could be used to control outbreaks...
  9. pmc The use of a mobile laboratory unit in support of patient management and epidemiological surveillance during the 2005 Marburg Outbreak in Angola
    Allen Grolla
    Special Pathogens Program, National Microbiology Laboratory, Public Health Agency of Canada, Winnipeg, Manitoba, Canada
    PLoS Negl Trop Dis 5:e1183. 2011
    ..Marburg virus (MARV), a zoonotic pathogen causing severe hemorrhagic fever in man, has emerged in Angola resulting in the largest outbreak of Marburg hemorrhagic fever (MHF) with the highest case fatality rate to date...
  10. pmc Ebola virus RNA editing depends on the primary editing site sequence and an upstream secondary structure
    Masfique Mehedi
    Department of Medical Microbiology, University of Manitoba, Winnipeg, Manitoba, Canada Laboratory of Virology, Rocky Mountain Laboratories, Division of Intramural Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Hamilton, Montana, United States of America
    PLoS Pathog 9:e1003677. 2013
    ..Overall, our results provide novel insights into the RNA editing mechanism of EBOV, further understanding of which might result in novel intervention strategies against this viral pathogen. ..
  11. pmc Viral hemorrhagic fevers: advancing the level of treatment
    Giuseppe Ippolito
    National Institute for Infectious Diseases Lazzaro Spallanzani, Rome, Italy
    BMC Med 10:31. 2012
    ..Here we discuss the current knowledge about VHF clinical management to propose a way to step up the approach to VHFs beyond the mere application of infection control measures...
  12. pmc Ebola haemorrhagic fever
    Heinz Feldmann
    Laboratory of Virology, Division of Intramural Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Rocky Mountain Laboratories, Hamilton, MT, USA
    Lancet 377:849-62. 2011
    ....
  13. pmc RNA polymerase I-driven minigenome system for Ebola viruses
    Allison Groseth
    National Laboratory for Zoonotic Diseases and Special Pathogens, National Microbiology Laboratory, Public Health Agency of Canada, Winnipeg, MB R3E 3R2, Canada
    J Virol 79:4425-33. 2005
    ....
  14. pmc A recently isolated Lassa virus from Mali demonstrates atypical clinical disease manifestations and decreased virulence in cynomolgus macaques
    David Safronetz
    Laboratory of Virology, Division of Intramural Research, NationalInstitute of Allergy and Infectious Diseases National Institutes of Health, Rocky Mountain Laboratories, Hamilton, Montana, USA
    J Infect Dis 207:1316-27. 2013
    ....
  15. pmc Chimeric human parainfluenza virus bearing the Ebola virus glycoprotein as the sole surface protein is immunogenic and highly protective against Ebola virus challenge
    Alexander Bukreyev
    National Institute of Allergy and Infectious Diseases, Building 50, Room 6505, NIAID, National Institutes of Health, 50 South Dr MSC 8007, Bethesda, MD 20892 8007, USA
    Virology 383:348-61. 2009
    ..Despite the attenuation, the virus was highly immunogenic, and a single IN dose completely protected the animals against a highly lethal intraperitoneal challenge of guinea pig-adapted EBOV...
  16. pmc Middle East respiratory syndrome coronavirus (MERS-CoV) causes transient lower respiratory tract infection in rhesus macaques
    Emmie de Wit
    Laboratory of Virology, Rocky Mountain Veterinary Branch, and Microscopy Unit, Research Technologies Branch, Division of Intramural Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Hamilton, MT 59840
    Proc Natl Acad Sci U S A 110:16598-603. 2013
    ..This tropism of MERS-CoV for the lower respiratory tract may explain the severity of the disease observed in humans and the, up to now, limited human-to-human transmission. ..
  17. ncbi request reprint Rescue of Ebola virus from cDNA using heterologous support proteins
    Steven Theriault
    Special Pathogens Program, National Laboratory for Zoonotic Diseases and Special Pathogens, National Microbiology Laboratory, Health Canada, Canada
    Virus Res 106:43-50. 2004
    ..In contrast to previous data, viral proteins were able to target heterologous filovirus RNA. Together these results indicated that protein-protein interactions are more critical than protein-RNA interactions...
  18. pmc Antibodies are necessary for rVSV/ZEBOV-GP-mediated protection against lethal Ebola virus challenge in nonhuman primates
    Andrea Marzi
    Laboratory of Virology, Rocky Mountain Laboratories, Division of Intramural Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Hamilton, MT 59840, USA
    Proc Natl Acad Sci U S A 110:1893-8. 2013
    ..Our results suggest that antibodies play a critical role in rVSV-mediated protection against ZEBOV...
  19. pmc Vesicular stomatitis virus-based vaccine protects hamsters against lethal challenge with Andes virus
    Kyle S Brown
    Department of Medical Microbiology, University of Manitoba, Winnipeg, Manitoba, Canada
    J Virol 85:12781-91. 2011
    ..Overall, our data suggest the potential for the use of the VSV platform as a fast-acting and effective prophylaxis/postexposure treatment against lethal hantavirus infections...
  20. ncbi request reprint In vitro evaluation of antisense RNA efficacy against filovirus infection, by use of reverse genetics
    Allison Groseth
    National Laboratory for Zoonotic Diseases and Special Pathogens, National Microbiology Laboratory, Public Health Agency of Canada
    J Infect Dis 196:S382-9. 2007
    ..Therefore, we explored the application of minigenomes as screening tools to identify functional siRNA targets under biosafety level 2 conditions...
  21. pmc Host response dynamics following lethal infection of rhesus macaques with Zaire ebolavirus
    Hideki Ebihara
    Laboratory of Virology, Rocky Mountain Veterinary Branch, Division of Intramural Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Rocky Mountain Laboratories, Hamilton, Montana 59840, USA
    J Infect Dis 204:S991-9. 2011
    ..These results highlight the pathological analogies between EHF and severe sepsis and not only contribute to our understanding of the pathogenic process, but will also help to establish novel postexposure treatment modalities...
  22. pmc Treatment with interferon-α2b and ribavirin improves outcome in MERS-CoV-infected rhesus macaques
    Darryl Falzarano
    Disease Modeling and Transmission Unit, Laboratory of Virology, Division of Intramural Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Rocky Mountain Laboratories, Hamilton, Montana, USA
    Nat Med 19:1313-7. 2013
    ..As these two drugs are already used in combination in the clinic for other infections, IFN-α2b and ribavirin should be considered for the management of MERS-CoV cases. ..
  23. pmc Comparative pathogenesis of three human and zoonotic SARS-CoV strains in cynomolgus macaques
    Barry Rockx
    Laboratory of Virology, Division of Intramural Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Hamilton, Montana, United States of America
    PLoS ONE 6:e18558. 2011
    ..This study characterizes critical disease models in the evaluation and licensure of therapeutic strategies against SARS-CoV for human use...
  24. pmc A novel model of lethal Hendra virus infection in African green monkeys and the effectiveness of ribavirin treatment
    Barry Rockx
    Laboratory of Virology, Division of Intramural Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, 903 S 4th Street, Hamilton, Montana, USA
    J Virol 84:9831-9. 2010
    ....
  25. pmc Adenovirus vectors expressing hantavirus proteins protect hamsters against lethal challenge with andes virus
    David Safronetz
    Department of Medical Microbiology, University of Manitoba, Winnipeg, Manitoba, Canada
    J Virol 83:7285-95. 2009
    ..These observations set the stage for a more detailed characterization of the types of immunity required to protect humans from hantavirus infections...
  26. pmc A Syrian golden hamster model recapitulating ebola hemorrhagic fever
    Hideki Ebihara
    Laboratory of Virology, Division of Intramural Research, National Institute of Allergy and Infectious Diseases NIAID, National Institutes of Health NID, Rocky Mountain Laboratories RML, Hamilton, Montana 59840, USA
    J Infect Dis 207:306-18. 2013
    ....
  27. pmc The adaptive immune response does not influence hantavirus disease or persistence in the Syrian hamster
    Joseph Prescott
    Laboratory of Virology, Division of Intramural Research, National Institute of Allergy and Infectious Disease, National Institutes of Health, Rocky Mountain Laboratories, Hamilton, MT, USA
    Immunology 140:168-78. 2013
    ..These data show that neither hantavirus replication, nor pathogenesis caused by these viruses, is influenced by the adaptive immune response in the Syrian hamster. ..
  28. pmc Experimental Andes virus infection in deer mice: characteristics of infection and clearance in a heterologous rodent host
    Jessica R Spengler
    Laboratory of Virology, Division of Intramural Research, National Institute of Allergy and Infectious Disease, National Institutes of Health, Rocky Mountain Laboratories, Hamilton, Montana, United States of America
    PLoS ONE 8:e55310. 2013
    ....
  29. pmc Effective post-exposure treatment of Ebola infection
    Heinz Feldmann
    Special Pathogens Program, National Microbiology Laboratory, Public Health Agency of Canada, Winnipeg, Manitoba, Canada
    PLoS Pathog 3:e2. 2007
    ....
  30. pmc Lethal Crimean-Congo hemorrhagic fever virus infection in interferon α/β receptor knockout mice is associated with high viral loads, proinflammatory responses, and coagulopathy
    Marko Zivcec
    Laboratory of Virology, Division of Intramural Research, National Institute Allergy and Infectious Disease, National Institutes of Health, Rocky Mountain Laboratories, Hamilton, Montana, USA
    J Infect Dis 207:1909-21. 2013
    ..Disease progression closely mimics hallmarks of human CCHF disease, making IFNAR(-/-) mice an excellent choice to assess medical countermeasures...
  31. pmc Vesicular stomatitis virus-based Ebola vaccines with improved cross-protective efficacy
    Andrea Marzi
    Laboratory of Virology, Division of Intramural Research, National Institute of Allergy and Infectious Diseases, National Institute of Health, Hamilton, Montana 59840, USA
    J Infect Dis 204:S1066-74. 2011
    ..Our data demonstrate that cross-protection between the EBOV species can be achieved, although EBOV-GP alone cannot induce the required immune response...
  32. pmc Protective efficacy of a bivalent recombinant vesicular stomatitis virus vaccine in the Syrian hamster model of lethal Ebola virus infection
    Yoshimi Tsuda
    Laboratory of Virology, Division of Intramural Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Hamilton, Montana, USA
    J Infect Dis 204:S1090-7. 2011
    ..Outbreaks of filoviral hemorrhagic fever occur sporadically and unpredictably across wide regions in central Africa and overlap with the occurrence of other infectious diseases of public health importance...
  33. pmc Enhanced protection against Ebola virus mediated by an improved adenovirus-based vaccine
    Jason S Richardson
    Special Pathogens Program, National Microbiology Laboratory, Public Health Agency of Canada, Winnipeg, Manitoba, Canada
    PLoS ONE 4:e5308. 2009
    ..The immune response elicited by this improved expression cassette vector (Ad-CAGoptZGP) and its ability to afford protection against lethal ZEBOV challenge in mice was compared to the standard Ad-CMVZGP vector...
  34. pmc The Middle East respiratory syndrome coronavirus (MERS-CoV) does not replicate in Syrian hamsters
    Emmie de Wit
    Laboratory of Virology, Division of Intramural Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Hamilton, Montana, United States of America
    PLoS ONE 8:e69127. 2013
    ..Clinical signs of disease, virus replication, histological lesions, cytokine upregulation nor seroconversion were observed in any of the inoculated animals, indicating that MERS-CoV does not replicate in Syrian hamsters. ..
  35. pmc Single immunization with a monovalent vesicular stomatitis virus-based vaccine protects nonhuman primates against heterologous challenge with Bundibugyo ebolavirus
    Darryl Falzarano
    Special Pathogens Program, National Microbiology Laboratory, Public Health Agency of Canada, Winnipeg, Canada
    J Infect Dis 204:S1082-9. 2011
    ....
  36. pmc Inclusion bodies are a site of ebolavirus replication
    Thomas Hoenen
    Laboratory for Virology, Division of Intramural Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Rocky Mountain Laboratories, Hamilton, Montana, USA
    J Virol 86:11779-88. 2012
    ..Based on these data we conclude that, rather than being inert aggregates of nucleocapsids, ebolavirus inclusion bodies are in fact complex and dynamic structures and an important site at which viral RNA replication takes place...
  37. ncbi request reprint Assessment of a vesicular stomatitis virus-based vaccine by use of the mouse model of Ebola virus hemorrhagic fever
    Steven M Jones
    Special Pathogens Program, National Microbiology Laboratory, Public Health Agency of Canada, Canada
    J Infect Dis 196:S404-12. 2007
    ..In the present study, we used the mouse model for Ebola hemorrhagic fever to assess the safety and efficacy of a vaccine based on a live attenuated vesicular stomatitis virus expressing the Zaire ebolavirus (ZEBOV) glycoprotein...
  38. pmc Assessment of rodents as animal models for Reston ebolavirus
    Emmie de Wit
    Laboratory of Virology, Division of Intramural Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Hamilton, Montana, USA
    J Infect Dis 204:S968-72. 2011
    ..Moreover, REBOV Pennsylvania was more pathogenic than REBOV Reston08-A in this model. Thus, STAT1(-)(/-) mice may be used for research of REBOV pathogenicity and intervention strategies...
  39. pmc Stimulation of Ebola virus production from persistent infection through activation of the Ras/MAPK pathway
    James E Strong
    Special Pathogens Program, National Microbiology Laboratory, Public Health Agency of Canada, Winnipeg, MB, Canada R3E 3R2
    Proc Natl Acad Sci U S A 105:17982-7. 2008
    ....
  40. ncbi request reprint Chimpanzee adenovirus vaccine protects against Zaire Ebola virus
    Gary P Kobinger
    Special Pathogens Program, National Microbiology Laboratory, Health Canada, Canadian Science Centre for Human and Animal Health, University of Manitoba, Winnipeg, Canada
    Virology 346:394-401. 2006
    ..These results validate further development of Chimpanzee-based vaccine and highlight the impact of pre-existing immunity to the vaccine carrier...
  41. pmc Immune parameters correlate with protection against ebola virus infection in rodents and nonhuman primates
    Gary Wong
    Special Pathogens Program, National Microbiology Laboratory, Public Health Agency of Canada, Winnipeg, Manitoba R3E 3R2, Canada
    Sci Transl Med 4:158ra146. 2012
    ..These results highlight the relevance of total ZGP-specific IgG levels as a meaningful correlate of protection against ZEBOV exposure...
  42. ncbi request reprint Live attenuated recombinant vaccine protects nonhuman primates against Ebola and Marburg viruses
    Steven M Jones
    Special Pathogens Program, National Microbiology Laboratory, Public Health Agency of Canada, 1015 Arlington Street, Winnipeg, Manitoba R3E 3R2, Canada
    Nat Med 11:786-90. 2005
    ..No evidence of EBOV or MARV replication was detected in any of the protected animals after challenge. Our data suggest that these vaccine candidates are safe and highly efficacious in a relevant animal model...
  43. pmc Rapid Nipah virus entry into the central nervous system of hamsters via the olfactory route
    Vincent J Munster
    Laboratory of Virology, Microscopy Unit, Division of Intramural Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Hamilton, MT, USA
    Sci Rep 2:736. 2012
    ..NiV entry into the CNS coincided with the occurrence of respiratory disease, suggesting that the initial entry of NiV into the CNS occurs simultaneously with, rather than as a result of, systemic virus replication...
  44. pmc Progress in filovirus vaccine development: evaluating the potential for clinical use
    Darryl Falzarano
    Laboratory of Virology, Rocky Mountain Laboratories, Division of Intramural Research, National Institute of Allergy and Infectious Disease, National Institutes of Health, 903 South 4th Street, Hamilton, MT 59840, USA
    Expert Rev Vaccines 10:63-77. 2011
    ..These results demonstrate that achieving a vaccine that is protective against filoviruses is possible; the challenge now is to prove its safety and efficacy in order to obtain a vaccine that is ready for human use...
  45. pmc Ebola GP-specific monoclonal antibodies protect mice and guinea pigs from lethal Ebola virus infection
    Xiangguo Qiu
    Special Pathogens Program, National Microbiology Laboratory, Public Health Agency of Canada, Winnipeg, Manitoba, Canada
    PLoS Negl Trop Dis 6:e1575. 2012
    ..These results indicate that MAbs particularly when used as an oligoclonal set are a potential therapeutic for post-exposure treatment of EBOV infection...
  46. ncbi request reprint Blockage of filoviral glycoprotein processing by use of a protein-based inhibitor
    Ute Stroher
    Special Pathogens Program, National Microbiology Laboratory, Public Health Agency of Canada, Manitoba, Canada R3E 3R2
    J Infect Dis 196:S271-5. 2007
    ..Thus, furin inhibitors are unlikely to be effective in the treatment of filoviral infections...
  47. ncbi request reprint Mucosal delivery of adenovirus-based vaccine protects against Ebola virus infection in mice
    Ami Patel
    Special Pathogens Program, National Microbiology Laboratory, Public Health Agency of Canada, Canada
    J Infect Dis 196:S413-20. 2007
    ....
  48. pmc Mucosal immunization of cynomolgus macaques with the VSVDeltaG/ZEBOVGP vaccine stimulates strong ebola GP-specific immune responses
    Xiangguo Qiu
    Special Pathogens Program, National Microbiology Laboratory, Public Health Agency of Canada, Winnipeg, Manitoba, Canada
    PLoS ONE 4:e5547. 2009
    ..Zaire ebolavirus (ZEBOV) produces a lethal viral hemorrhagic fever in humans and non-human primates...
  49. pmc Pandemic swine-origin H1N1 influenza A virus isolates show heterogeneous virulence in macaques
    David Safronetz
    Laboratory of Virology, Hamilton, Montana, USA
    J Virol 85:1214-23. 2011
    ..Differences in virulence may explain more severe disease, as was seen with certain individuals infected with the emerged pandemic influenza virus. Thus, the nonhuman primate model closely mimics influenza in humans...
  50. pmc Validation of assays to monitor immune responses in the Syrian golden hamster (Mesocricetus auratus)
    Marko Zivcec
    Laboratory of Virology, Division of Intramural Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Hamilton, MT, USA
    J Immunol Methods 368:24-35. 2011
    ..Ribosomal protein L18 was identified as the most stable internal reference gene. In conclusion, these new assays will greatly improve the use of the hamster as an important small animal model in infectious disease research...
  51. pmc Hamster-adapted Sin Nombre virus causes disseminated infection and efficiently replicates in pulmonary endothelial cells without signs of disease
    David Safronetz
    Laboratory of Virology, Division of Intramural Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Rocky Mountain Laboratories, Hamilton, Montana, USA
    J Virol 87:4778-82. 2013
    ..We found that a host-adapted SNV achieves prolonged and disseminated infection in hamsters, including efficient replication in pulmonary endothelial cells, albeit without signs of disease...
  52. pmc A new Ebola virus nonstructural glycoprotein expressed through RNA editing
    Masfique Mehedi
    Department of Medical Microbiology, University of Manitoba, Public Health Agency of Canada, Winnipeg, Manitoba, Canada
    J Virol 85:5406-14. 2011
    ..While ssGP appears to share similar structural properties with sGP, it does not appear to have the same anti-inflammatory function on endothelial cells as sGP...
  53. pmc Clinical outcome of henipavirus infection in hamsters is determined by the route and dose of infection
    Barry Rockx
    Laboratory of Virology, Division of Intramural Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Hamilton, Montana, USA
    J Virol 85:7658-71. 2011
    ....
  54. pmc The immune response to Nipah virus infection
    Joseph Prescott
    Laboratory of Virology, Division of Intramural Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Hamilton, MT, USA
    Arch Virol 157:1635-41. 2012
    ..This review summarizes our current understanding of the immune response to Nipah virus infection and emphasizes the need for further research...
  55. pmc Enhanced detection of Rift Valley fever virus using molecular assays on whole blood samples
    Allen Grolla
    Zoonotic Diseases and Special Pathogens, National Microbiology Laboratory, Public Health Agency of Canada, Winnipeg, Manitoba, Canada
    J Clin Virol 54:313-7. 2012
    ..In December 2006, an RVF outbreak was recognized in Kenya which led to the deployment of international response laboratory teams to the area...
  56. pmc Antagonism of type I interferon responses by new world hantaviruses
    Jessica R Levine
    Rocky Mountain Laboratories, Hamilton, MT 59840, USA
    J Virol 84:11790-801. 2010
    ..These data suggest that IFN antagonism strategies by hantaviruses are quite variable, even between species with similar disease phenotypes, and may help to better elucidate species-specific pathogenesis...
  57. pmc Functional analysis of the noncoding regions of the Uukuniemi virus (Bunyaviridae) RNA segments
    Kirsten Flick
    Special Pathogens Program, National Microbiology Laboratory, Health Canada, Canadian Science Centre for Human and Animal Health, Winnipeg
    J Virol 78:11726-38. 2004
    ..Based on promoter strength, M-segment NCRs may be the preferred choice for the development of reverse genetics and minigenome rescue systems for bunyaviruses...
  58. pmc Nipah virus transmission in a hamster model
    Emmie de Wit
    Laboratory of Virology, Division of Intramural Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Hamilton, Montana, USA
    PLoS Negl Trop Dis 5:e1432. 2011
    ..The data provide new and much-needed insights into the modes and efficiency of Nipah virus transmission and have important public health implications with regards to the risk assessment and management of future Nipah virus outbreaks...
  59. ncbi request reprint Ebola sGP--the first viral glycoprotein shown to be C-mannosylated
    Darryl Falzarano
    Department of Medical Microbiology, University of Manitoba, Winnipeg, Manitoba, Canada R3E 0W3
    Virology 368:83-90. 2007
    ..In this regard, C-mannosylation of sGP may be an anomaly resulting from the unique manner in which this protein is generated as the product of unedited transcripts from the glycoprotein gene of Ebola...
  60. ncbi request reprint Aberrant innate immune response in lethal infection of macaques with the 1918 influenza virus
    Darwyn Kobasa
    Respiratory Viruses, Public Health Agency of Canada, Winnipeg, Manitoba R3E 3R2, Canada
    Nature 445:319-23. 2007
    ..The ability of influenza viruses to modulate host immune responses, such as that demonstrated for the avian H5N1 influenza viruses, may be a feature shared by the virulent influenza viruses...
  61. ncbi request reprint Progress towards the treatment of Ebola haemorrhagic fever
    Ute Stroher
    National Microbiology Laboratory, Public Health Agency of Canada, 1015 Arlington Street, Winnipeg, Manitoba, R3E3R2, Canada
    Expert Opin Investig Drugs 15:1523-35. 2006
    ..The current development in this field encourages discussions on how to move some of the experimental approaches towards clinical application...
  62. ncbi request reprint Severe acute respiratory syndrome-related coronavirus is inhibited by interferon- alpha
    Ute Stroher
    National Microbiology Laboratory, Health Canada, and Department of Medical Microbiology, University of Manitoba, Winnipeg, Canada
    J Infect Dis 189:1164-7. 2004
    ..In conclusion, ribavirin alone is unlikely to be beneficial in the prophylaxis or treatment of SARS CoV infections. Clinical trials with IFN- alpha might be justified to determine a beneficial effect on the outcome of SARS...
  63. pmc Properties of replication-competent vesicular stomatitis virus vectors expressing glycoproteins of filoviruses and arenaviruses
    Michael Garbutt
    Special Pathogens Program, National Microbiology Laboratory, Health Canada, Winnipeg, Manitoba, Canada R3E 3R2
    J Virol 78:5458-65. 2004
    ..Our data suggest that the recombinant VSV can be used to study the role of the viral glycoproteins in virus replication, immune response, and pathogenesis...
  64. pmc Current ebola vaccines
    Thomas Hoenen
    National Institute of Allergy and Infectious Diseases, National Institutes of Health, Division of Intramural Research, Rocky Mountain Laboratories, Disease Modelling and Transmission Unit Laboratory of Virology, 2A120A, 903 S 4th St, Hamilton, MT, USA
    Expert Opin Biol Ther 12:859-72. 2012
    ..However, a number of vaccine candidates have been developed in the last decade that are highly protective in NHPs, the gold standard animal model for ebola hemorrhagic fever...
  65. pmc Thoracic radiography as a refinement methodology for the study of H1N1 influenza in cynomologus macaques (Macaca fascicularis)
    Douglas L Brining
    Rocky Mountain Veterinary Branch, Division of Intramural Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Hamilton, Montana, USA
    Comp Med 60:389-95. 2010
    ..The radiographic evaluation allowed for noninvasive assessment of lung involvement, disease onset, progression, and resolution of radiographic changes associated with H1N1 influenza infection...
  66. pmc A replicating cytomegalovirus-based vaccine encoding a single Ebola virus nucleoprotein CTL epitope confers protection against Ebola virus
    Yoshimi Tsuda
    Laboratory of Virology, Division of Intramural Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Hamilton, Montana, United States of America
    PLoS Negl Trop Dis 5:e1275. 2011
    ....
  67. pmc Modern dosimetric tools for (60)Co irradiation at high containment laboratories
    Barri Twardoski
    Radiation Safety Department, Division of Intramural Research, National Institute of Allergy and Infectious Diseases, NIH, Rocky Mountain Laboratories, Hamilton, MT 59840, USA
    Int J Radiat Biol 87:1039-44. 2011
    ....
  68. pmc Protective efficacy of neutralizing monoclonal antibodies in a nonhuman primate model of Ebola hemorrhagic fever
    Andrea Marzi
    Laboratory of Virology, Rocky Mountain Laboratories, Division of Intramural Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Hamilton, Montana, USA
    PLoS ONE 7:e36192. 2012
    ..Our results indicate that EBOV neutralizing antibodies, particularly in combination with other therapeutic strategies, might be beneficial in reducing viral loads and prolonging disease progression during EHF...
  69. pmc The Syrian hamster model of hantavirus pulmonary syndrome
    David Safronetz
    Laboratory of Virology, Division of Intramural Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, 903 South 4th Street, Hamilton, MT 59840, USA
    Antiviral Res 95:282-92. 2012
    ..The purpose of this article is to review the current understanding of HPS disease progression in Syrian hamsters and discuss the suitability of utilizing this model to evaluate potential medical countermeasures against HPS...
  70. pmc Tackling Ebola: new insights into prophylactic and therapeutic intervention strategies
    Emmie de Wit
    Laboratory of Virology, Division of Intramural Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Hamilton, 903 South 4th Street, MT 59840, USA
    Genome Med 3:5. 2011
    ..Here, we review the current state of Ebolavirus research, with emphasis on prophylactic and therapeutic intervention strategies...
  71. pmc Ebola virion attachment and entry into human macrophages profoundly effects early cellular gene expression
    Victoria Wahl-Jensen
    Integrated Research Facility at Fort Detrick, Division of Clinical Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Fort Detrick, Maryland, United States of America
    PLoS Negl Trop Dis 5:e1359. 2011
    ..In contrast, VLP(VP40) (particles lacking GP(1,2)) caused an aberrant response. This suggests that GP(1,2) binding to macrophages plays an important role in the immediate cellular response...